Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


1 10, 2015

Genetics and individualized myeloma therapy

Tags: , , |0 Comments

An important prognostic development was announced earlier this year by researchers in England. Check out this excerpt from MedPageToday's special report, Mutations in Myeloma Predict Outcome: The identification of 15 clinically relevant mutations in myeloma and the development of an international staging system mutation score (ISS-MUT) may make it possible to stratify patients with myeloma

23 09, 2015

Update on ixazomib

Tags: , , , |4 Comments

Don't sleep on ixazomib. My sources tell me to expect a flood of positive data about Takeda's oral proteasome inhibitor (MLN9708) at this year's ASH in Orlando. We should get a glimpse of things to come at the 15th International Myeloma Workshop (IMW 2015) in Rome, Italy, from September 23 to 26, 2015. Ixazomib is

9 09, 2015

Ixazomib granted priority review by FDA

Tags: , , |0 Comments

The myeloma world doesn't stop spinning just because I'm waiting for test results. With so much excitement surrounding the immunotherapies elotuzumab and daratumumab, another promising new drug, ixazomib (MLN9708), is often overlooked. That's a mistake, especially for patients that have successfully responded to Velcade and/or Kyprolis. This morning the FDA granted the oral proteasome inhibitor

2 09, 2015

Two promising new myeloma therapies: ABT-199 and daratumumab

Tags: , |4 Comments

I just heard from a patient's daughter. Her mother is joining a clinical trial for ABT-199 at Mayo Clinic in Minnesota. Apparently the myeloma team there is openly enthusiastic about the drug's potential. ABT-199 is a Bcl-2 inhibitor, targeting the BCL-2 protein. The experimental drug has produced remarkable success against several other types of blood

27 08, 2015

BREAKING NEWS: Daratumumab pushes forward toward FDA approval

Tags: , , , , |1 Comment

Important news as the promising new immunotherapy, daratumumab, continues to move swiftly toward FDA approval. My friends at Genmab and Jannsen in the Netherlands emailed me details last evening, along with some helpful background information to review: Daratumumab is an investigational human anti-CD38 monoclonal antibody that received Breakthrough Therapy Designation from the FDA in May,

21 08, 2015

CrowdCare Foundation betting on T cell therapy

Tags: , |1 Comment

After hearing from dozens of you about your peripheral neuropathy--and what you do to help minimize the symptoms--I'm working on a two part series about it, sharing tips from more than 20 patients; I'll run the posts this weekend. In the meantime, here is CrowdCare Foundation's official press release, announcing our support for two important,

14 08, 2015

Understanding our future: immunotherapies

Tags: , , |2 Comments

I just listened to one of the best and easiest to understand videos I've found, explaining how the new monoclonal antibodies (elotuzumab and daratumumab) work. My good friend and long lived myeloma survivor, Jack Aiello, is interviewing Dana-Farber's Dr. Paul Richardson on a Patient Power broadcast. It's short and to the point. Give it a

12 08, 2015

BREAKING NEWS: MMRF helps push expanded access for dararumumab

Tags: , , , |2 Comments

Today is your last chance to participate in a focus group study using your smart phones. Amazon gift cards will be given to all who participate. Contact Kristin Mraz,Community Recruitment Manager - WEGO Health, 177 Tremont Street, 3rd Floor,Boston, MA,02111 - cell:  518.774.6114 - office:  617.863.7745 - fax:  617.426.5027 - I've worked with these

5 08, 2015

New myeloma staging system long overdue

Tags: , |8 Comments

I think most myeloma experts would agree: its time for a myeloma staging system that incorporates genetic risk assessment. Italian specialist, Dr. Palumbo, and his team are proposing docs worldwide use their new system. Health Day gave Dr. Palumbo a shout out yesterday: Revised staging system prognostic for multiple myeloma August 4th, 2015 (HealthDay)—The International